NCT00311363View on ClinicalTrials.gov

Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.

PHASE3CompletedINTERVENTIONAL

Enrollment

327

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Restless Legs Syndrome

Interventions

DRUG

GEn (XP13512)

1200 mg GEn (XP13512) orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks

DRUG

GEn (XP13512)

1200 mg GEn (XP13512), orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks

DRUG

Placebo

Placebo, orally, once daily for 12 weeks following single blind 24-week phase

All Listed Sponsors

lead

XenoPort, Inc.

INDUSTRY

NCT00311363 - Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome. | Biotech Hunter | Biotech Hunter